Innovation and collaboration drive NYGC’s mission. At NYGC, our team is eager to collaborate with you in planning a successful genomics research project from inception to completion. We are flexible and creative, and work to meet the needs of our partners by designing tailor-made collaborations covering a spectrum of opportunities. NYGC has established successful partnerships with over 600 researchers and clinicians from top academic institutions as well as pharma, biotechnology, diagnostics, genomics, and big data analysis companies around the world. Our collaborative research environment and successful execution of advanced genomic collaborative research facilitates our mission for the advancement of science and technology related to the diagnosis and treatment of serious disease.
Below we describe our efforts in three areas, i.e., Industry and Foundation Strategic Collaborations, Academic Collaborations and Disease Specific Consortia.Please connect with our team to explore ways that NYGC can help facilitate and successfully complete genomics research at firstname.lastname@example.org.
Industry and foundation collaborations
NYGC is an independent nonprofit established through strong relationships and affiliations with leading medical and academic institutions in New York and beyond. We have conducted more than 2200 genomics research projects and clinical diagnostic testing in collaboration with academic institutions, disease foundations and industry, including several top 10 pharmaceutical companies. Through these strategic partnerships, we look to accelerate knowledge creation and discovery to impact the scientific and medical communities and advance our mission.
Potential collaborative project examples:
To learn more about the ways that NYGC can help support your genomics research projects, contact us at email@example.com.
- Assess combined results of patient genome sequencing and RNA-Seq to identify signatures that are common within exceptional groups and differ between them
- Analyze ongoing clinical trials or banked patient samples to:
- Identify genetic differentiators to stratify patients for future clinical trials
- Define biomarkers for a companion diagnostic (CDx)
- Discover new clinically relevant pathways
- Inform rational combination of therapies
- Revive a shelved drug
- Participate in NYGC’s disease-specific consortia to contribute to the understanding of how mutations cause disease and to enhance definitive diagnosis and effective drug discovery efforts
- Develop cutting-edge approaches with our Innovation Laboratory to create and advance new sequencing applications to meet your research needs, including in the areas of:
- Single Cell Sequencing
- Methods Development
- Long Read Next-Generation Sequencing
- Collaborate with our Genome Engineering and Functional Discover Platform (GEFDP) to access high-throughput CRISPR screening technology
Genome Engineering and Functional Discovery Platform
Applying High-Throughput CRISPR Gene Editing for Functional Genomic Screening and Target Identification at NYGC
The Genome Engineering and Functional Discovery Platform (GEFDP) at NYGC works with collaborative partners to establish and carry out high-throughput genome editing screens to functionally query emerging disease systems. These functional genomics methods include genome-wide loss-of-function and gain-of-function screens in vitro and in vivo, as well as scanning mutagenesis to identify functional elements in the noncoding genome. In addition to developing and optimizing new gene editing technologies and pooled screening assays, GEFDP scientists have built the computational tools necessary to analyze genome-wide datasets for functional discoveries.
Specific goals of this platform technology
GEFDP scientists support collaborators to design and implement high-throughput screens to investigate the effect of genetic alterations on biologic phenotypes of interest including:
- Pooled CRISPR library design, synthesis and production
- Cell culture library screening
- Sequencing and data analysis
- Array screen to validate primary screen hits
Join the GEFDP as a collaborative partner
The GEFDP scientific team engages with academic and industry collaborators from experimental design through project execution to optimize the biological system and depth of discovery. The expertise of the GEFDP scientists enables collaborators to deploy high-throughput screening technology to:
For more information on the Genome Engineering and Functional Discovery Platform at NYGC, please contact firstname.lastname@example.org.
- Understand resistance mechanisms to a drug of interest
- Identify disease-relevant genetic variants
- Discover new clinically actionable pathways
- Investigate noncoding and regulatory elements
Through academic collaborations, NYGC seeks to cultivate research projects in support of our mission of savings lives by transforming biomedical research. NYGC advances scientific progress by helping researchers and physicians generate, manage, and understand genomics data, through sequencing and bioinformatics services, interpretive collaboration and training.
NYGC conducts research in collaboration with our member institutions as well as other leaders in academia and industry around the world. NYGC also leads disease-specific consortia that are open to additional academic and industry partners. We welcome collaborations with academic institutions and hospitals to advance clinically actionable genomics.Please connect with our team to explore possibilities for academic collaboration by contacting email@example.com.
NYGC consortia enable our partners to leverage our links with academic institutions, disease foundations and pharmaceutical industry resources to create centers of excellence for genomics research in specific disease areas, including to:
- Empower clinical informatics
- Advance biospecimen collection
- Enable complex data analysis
- Develop functional genomics programs
- Propel data warehousing
Sequencing well-stratified cohorts and harmonizing clinical phenotyping in a consortium effort can enable the integration of genomic and clinical data to identify genetic modifiers of disease onset, progression and presentation.
JOIN OUR CONSORTIA
NYGC Consortia is open to establishing additional disease area consortia. If you are interested in participating in a new disease-specific consortium with us, please contact us at firstname.lastname@example.org
The current NYGC Consortia are open to additional academic and industry partners. If you are interested in joining any of our consortia, please contact us at email@example.com
Currently, NYGC has established the following consortia:
NYGC ALS Consortium
The Center for Genomics of Neurodegenerative Disease (CGND) at NYGC has formed an ALS Consortium involving alliances with clinicians, scientists, geneticists, computational biologists, and industry partners. The primary goal is to discover mutations underlying ALS and to understand how they cause disease. The Consortium establishes a framework to apply clinical and functional genomics together with bioinformatics to the study of ALS disease mechanisms.
Since its inception just over a year ago, the NYGC ALS Consortium has grown to include 15 institutions. Our efforts synergize with other ALSA-funded consortia, such as the Genomics Translation for Clinical Care (GTAC) Consortium headquartered at Columbia University. The NYGC and Columbia University efforts comprise the largest and best characterized ALS study to date with a target to complete whole genome sequencing and analysis of 3,200 clinically well-annotated samples within the next three years.
Specific goals of the ALS Consortium:
To join the ALS Consortium, or for more information, please contact firstname.lastname@example.org.
- Integrate genomic and clinical data to identify genetic modifiers of ALS disease onset, progression and presentation
- Combine whole genome sequencing with RNA sequencing
- Build functional genomics program: design, create, and share ALS models to study mutation effects in stem cell-derived neurons and mice
- Create and maintain a data warehouse for genomic data that can ultimately be broadly accessed by and freely available to the academic community
The NYGC and Industry Partners Cancer Genomics Alliance (NYGC Cancer Alliance)
Existing cancer genomic data is growing, but is limited. The NYGC Cancer Alliance aims to advance the clinical study of cancer therapies and genomic data with the goal of improving patient care. The repository built by this Alliance provides access to data from clinically well-annotated tumor and paired normal samples, in addition to whole genome sequencing, whole exome sequencing, sequencing panels, RNA sequencing and epigenetic studies. These cancer patients have failed conventional therapy, but have a life expectancy of one to three years, providing an opportunity for meaningful intervention. Additionally, the data repository can be utilized in multiple ways, including the identification of genetic differentiators to stratify patients for clinical trials and inform rational combination of therapies, the defining of biomarkers for clinical diagnostics, and to discover new clinically relevant pathways.
The NYGC Cancer Alliance is actively engaged with multiple top-tier partner academic institutions and hospitals to collect patient samples and clinical information. In Phase I, the NYGC Cancer Alliance will sequence 200 cancer patients (funded by IBM as the Founding Industry Partner). The NYGC Cancer Alliance is seeking additional industry partners to fund Phase II and beyond.To join the NYGC Cancer Alliance, or for more information, please contact email@example.com.
Technology transfer at NYGC involves dedicated personnel who identify research results (e.g., patentable inventions, tangible materials and/or copyrighted materials) which may generate potential commercial interest. Strategies are then deployed to facilitate appropriate transfer of these technologies to for-profit entities for further development which hopefully leads to commercialization. The process for transferring technologies may vary. It can involve licensing agreements or setting up joint ventures or other forms of alliances to share both the risks and rewards of bringing new technologies to market. Other corporate vehicles, e.g., spin-outs, might be used where NYGC does not have the necessary interest, resources and/or skills to develop a new technology.
NYGC has the following technologies available for transfer:If you are interested in learning more about one of more of these technologies, please contact NYGC at firstname.lastname@example.org.
The Sponsored Research team serves as a resource in support of the faculty and staff in their research activities at NYGC and in their collaborations with partner institutions. The team works with researchers on sponsored projects from concept to proposal to award, and coordinates all aspects of grant management and compliance.If you are interested in learning more, please contact email@example.com.